(Q80539568)

English

A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study

scientific article published on 27 June 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597196%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597196%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Deborah J Stearns-Kurosawa

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597196%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

D Scott McMeekin

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597196%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Michael W Sill

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597196%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Kathleen M Darcy

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597196%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Kenneth Webster

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597196%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Steven Waggoner

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597196%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Doris Benbrook

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597196%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

27 June 2007

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597196%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597196%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

106

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597196%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597196%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

596-603

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597196%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Patterns of metastasis in uterine sarcoma. An autopsy study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Clinical translation of angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF).

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

VEGF as a key mediator of angiogenesis in cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Differential expression of angiogenesis-related genes in human gastric cancers with and those without high-frequency microsatellite instability.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Prognostic significance of vascular endothelial growth factor protein levels in T1-2 N0 laryngeal cancer treated with primary radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Markers of angiogenesis and clinical features in patients with sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Vascular endothelial growth factor and soft tissue sarcomas: tumor expression correlates with grade

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Cytosol Vascular Endothelial Growth Factor in Endometrial Carcinoma: Correlation with Disease-Free Survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

The angiogenic ?vascular endothelial growth factor/flk-1(KDR) receptor? pathway in patients with endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Prognostic significance of vascular endothelial growth factor and its receptors in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

VEGF and its receptors (flt-1 and KDR/flk-1) as prognostic indicators in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

VEGF, flt-1, and KDR/flk-1 as prognostic indicators in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Tumor angiogenesis: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

The thalidomide saga

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Angiogenesis in malignancies of the female genital tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Response to thalidomide in multiple myeloma: impact of angiogenic factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Ovarian cancer, the coagulation pathway, and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Activated protein C promotes breast cancer cell migration through interactions with EPCR and PAR-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Role of current and emerging antithrombotics in thrombosis and cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Involvement of platelets in tumour angiogenesis?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Optimal flexible designs in phase II clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Ovarian and papillary-serous peritoneal carcinoma: pilot study with thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Independent prognostic importance of microvessel density in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Angiogenesis of endometrial carcinomas assessed by measurement of intratumoral blood flow, microvessel density, and vascular endothelial growth factor levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Biomarkers of intrinsic angiogenic and anti-angiogenic activity in patients with endometrial hyperplasia and endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Challenges for patient selection with VEGF inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Expression of the vascular endothelial cell protein C receptor in epithelial tumour cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon alfa-2a.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.05.013

7 January 2021

Identifiers

10.1016/J.YGYNO.2007.05.013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597196%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17597196%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q80539568&oldid=1755831047"